Global Gilenya Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Gilenya Market Research Report 2024
Gilenya is an immunomodulating drug, mostly used for treating multiple sclerosis (MS). Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction.
According to Mr Accuracy reports new survey, global Gilenya market is projected to reach US$ 934.9 million in 2029, increasing from US$ 2013 million in 2022, with the CAGR of -8.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gilenya market research.
The Gilenya market is primarily driven by the growing demand for effective treatments for multiple sclerosis (MS), particularly relapsing forms of the disease. Gilenya (fingolimod) is an oral medication that modulates immune system responses, aiming to reduce relapses and slow down disease progression. The increasing prevalence of MS and the need for therapies that offer convenience and improved quality of life contribute to market growth. Moreover, the shift from injectable to oral treatments and the potential to decrease relapse rates further propel adoption. However, challenges include potential cardiac effects during the initial dose and the need for monitoring patients for safety. Navigating the competitive landscape of MS treatments and addressing affordability and access barriers for a wider patient population are ongoing concerns. The market's success hinges on continuous research to enhance safety profiles, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and MS patient organizations to optimize MS management while addressing the evolving challenges associated with Gilenya therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gilenya market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis
Segment by Type
28 Capsules/Box
96 Capsules/Box
Retail Pharmacy
Hospital Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Gilenya report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Gilenya market is projected to reach US$ 934.9 million in 2029, increasing from US$ 2013 million in 2022, with the CAGR of -8.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Gilenya market research.
The Gilenya market is primarily driven by the growing demand for effective treatments for multiple sclerosis (MS), particularly relapsing forms of the disease. Gilenya (fingolimod) is an oral medication that modulates immune system responses, aiming to reduce relapses and slow down disease progression. The increasing prevalence of MS and the need for therapies that offer convenience and improved quality of life contribute to market growth. Moreover, the shift from injectable to oral treatments and the potential to decrease relapse rates further propel adoption. However, challenges include potential cardiac effects during the initial dose and the need for monitoring patients for safety. Navigating the competitive landscape of MS treatments and addressing affordability and access barriers for a wider patient population are ongoing concerns. The market's success hinges on continuous research to enhance safety profiles, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and MS patient organizations to optimize MS management while addressing the evolving challenges associated with Gilenya therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gilenya market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Segment by Type
28 Capsules/Box
96 Capsules/Box
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Gilenya report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices